Ars Pharmaceuticals Inc (SPRY)
EBITDA Margin
-177.04%
TTM · Period ending:
SPRY EBITDA Margin
Latest reported-177.04%period ending
Latest reported-177.04%period ending
SPRY TTM EBITDA Margin (-1301.78% → -177.04%)
TTM ebitda margin
High-resolution chart · PNG
SPRY ebitda margin history
Trailing twelve months (TTM). Each value covers four complete reported quarters.
| Period ending | EBITDA Margin |
|---|---|
| -177.0421% | |
| -194.1386% | |
| -199.3996% | |
| -53.7101% | |
| -41.8296% | |
| -15.3261% | |
| 9.5279% | |
| -1,909.7352% | |
| -8,956% | |
| -496,320% | |
| -180,973.3333% | |
| -205,170% | |
| -24,329.6804% | |
| -6,220.5052% | |
| -2,592.9331% | |
| -1,179.6135% | |
| -959.3607% | |
| -525.8442% | |
| -328.8413% | |
| -547.4747% | |
| -634.6354% | |
| -1,301.7756% |